腺病毒介导的RNA干扰ERCC1基因表达对逆转卵巢癌顺铂耐药的效果

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1399 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of cisplatin resistance being reversed in ovarian cancer by adenovirus-mediated RNA interference with ERCC1 gene expression.Methods The cisplatin-resistant SKOV3/DDP cells were directly infected with the recombinant adenovirus, and trypan blue counting, MTT, Hoechst staining and flow cytometry were used in this study. The growth curve, doubling time, IC₅₀ value, apoptotic morphology and cell cycle scores of SKOV3/DDP cells before and after infection were detected.Results (1) The inhibition rate of SKOV3/DDP cells was positively correlated with the concentration of cisplatin. The correlation coefficient r=0.9862 (P<0.05). The IC₅₀ value of cisplatin was (13.93±0.37)μg/ml, and the resistance index was 1.79. (2) The sensitivity of SKOV₃/DDP cells to cisplatin increased by 11.1%, 16.7%, 26.4% and 33.5% respectively in a dose-dependent manner (r=0.9716, P<0.05) after being infected with the recombinant adenovirus, and the drug resistance index decreased to 1.19. (3) The proportion of G1 phase cells, S phase cells and apoptotic rate of SKOV3/DDP cells increased (P<0.05) after being infected with the recombinant adenovirus combined with cisplatin.Conclusions Interference with ERCC1 gene expressions can reverse cisplatin resistance in cisplatin-resistant ovarian cancer cell line SKOV3/DDP cells by inducing apoptosis and regulating cell cycle distribution.

Key words： ovarian carcinoma ERCC1 gene RNA interference cisplatin recombinant adenovirus expression vector

Received: 20 October 2018

ZTFLH:

R731.31

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2019/V30/I7/591

[1]	Harries M,Kaye S B. Recent advances in the treatment of epithelial ovarian cancer [J]. Expert Opin Investig Drugs, 2001, 10(9):1715-1724.
[2]	Ferry K V,Hamllton T C,Johnson S W. Increased nucleo-tide excision repair in cisplatin-resistant ovarian cancer: role of ERCC1-XPF[J]. Biochem Phanmacol, 2000,60(9): 1305-1313.
[3]	于艳丽,韩萍,田志华.上皮性卵巢癌DNA-PKcs、ERCC1表达与耐药相关因素分析[J].疑难病杂志, 2013,6(12):443-445.
[4]	刘微, 毕秋英,瞿全新,等.带hTERT启动子的腺病毒干扰ERCC1基因表达逆转卵巢癌顺铂耐药的研究[J].现代妇产科进展, 2012,21(4):246-249,254.
[5]	田丽娜,瞿全新,盛晓滨,等.腺病毒介导的RNA干扰ERCC1基因表达对卵巢癌顺铂化疗的增敏作用[J].武警医学,2018,29(4):361-366.
[6]	王会妍,瞿全新.卵巢上皮性卵巢癌ERCC1表达与顺铂化疗耐药关系的研究[J].现代妇产科进展, 2006,7(15):512-514.
[7]	刘静,瞿全新,糜若然.RNA干扰ERCC1基因表达卵巢癌细胞耐药的影响[J].河北医学, 2006,9(12):893-895.
[8]	高赟,苏丹,应莉沙,等.RNA干扰ERCC1基因表达对肺腺癌细胞A549/DDP顺铂耐药的影响[J].中国肺癌杂志, 2010,9(13):846-849.
[9]	唐琳,梁军,李玉军.上皮性卵巢癌ERCC1表达与顺铂耐药的关系[J].齐鲁医学杂志, 2009,10(24):388-390.
[10]	陈国强,颜露春,左瑜芳,等.人卵巢癌组织中BRCA1、PRP13、TUBB3及ERCC1基因表达及其与化疗耐药的关系[J].实用肿瘤杂志, 2018,33(5):432-435.
[11]	李雪梅,姚嘉斐.端粒酶抑制剂对顺铂不同敏感性卵巢癌细胞株的影响[J].实用妇产科杂志, 2006,2(22):86-88.